This company has been acquired
RAPT Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 3.2yrs |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
Jan 20We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate
Jul 16
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Mar 28Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904
Feb 16Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?
Nov 10RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15CEO
RAPT Therapeutics has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Strategic Consultant | 10.8yrs | US$2.31m | 0.0079% $ 141.4k | |
| President | no data | no data | no data | |
| Vice President of Technology | no data | no data | no data | |
| Chief Scientific Officer | 6.8yrs | US$1.48m | no data | |
| General Counsel | 3.2yrs | no data | no data | |
| Senior Vice President of Biology | 6yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 3.5yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2.1yrs | no data | no data | |
| Senior Vice President of Business Development & Strategy | 1.1yrs | no data | no data | |
| VP, Treasurer & Director | no data | no data | no data |
Experienced Management: RAPT's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | no data | no data | |
| VP, Treasurer & Director | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data |
Experienced Board: RAPT's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 00:43 |
| End of Day Share Price | 2026/03/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RAPT Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gao Yi Chen | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Zegbeh Jallah | Capital One Securities, Inc. |